Clinical Trials Logo
  1. Home
  2. Liver Cirrhosis
  3. NCT03476993

Non-comparative Study of BCD-085 in Combination With UDCA in Patients With Primary Biliary Cholangitis

Liver Cirrhosis, Biliary Clinical Trial

Official title:
Open-label Non-comparative Study to Evaluate the Efficacy and Safety of BCD-085 (JSC BIOCAD, Russia) in Combination With Ursodeoxycholic Acid in Patients With Primary Biliary Cholangitis

Clinical Trial Summary

BCD-085 is an innovative drug, anti-interleukin-17 monoclonal antibody. The aim of the study is to evaluate the efficacy and safety of BCD-085 in patients with primary biliary cholangitis (PBC).

Clinical Trial Description

This is an open-label proof-of-concept phase 2A study. The aim of the study is to evaluate the efficacy and safety of BCD-085 in combination with ursodeoxycholic acid in patients with primary biliary cholangitis (PBC) with compensated liver function with an inadequate (suboptimal) response to ursodeoxycholic acid.

In this study the inadequate (suboptimal) response to ursodeoxycholic acid (UDCA) is defined as screening alkaline phosphatase (ALP) level > 1.67 ULN (the upper limit of normal) despite treatment with UDCA in stable dose for at least 6 months before signing the ICF. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03476993
Study type Interventional
Source Biocad
Contact
Status Terminated
Phase Phase 2
Start date April 27, 2018
Completion date July 1, 2019
View Details
See also
  Status Clinical Trial Phase
Completed NCT02917408 - Retrospective Study About Primary Biliary Cholangitis During January 2001 to July 2016 at West China Hospital
Terminated NCT00550862 - Study of INT 747 in Combination With URSO in Patients With Primay Biliary Cirrhosis (PBC) Phase 2
Completed NCT00004748 - Low-Dose Oral Methotrexate Versus Colchicine for Primary Biliary Cirrhosis Phase 3
Completed NCT03630718 - Trial of Psychoeducational and Hypnosis Interventions on the Fatigue Associated With PBC in Women N/A
Completed NCT00004842 - Pilot Study of Budesonide for Patients With Primary Sclerosing Cholangitis Phase 1
Terminated NCT03633227 - Study of Obeticholic Acid (OCA) Evaluating Pharmacokinetics and Safety in Participants With Primary Biliary Cholangitis (PBC) and Hepatic Impairment Phase 4
Terminated NCT00125281 - SAMe to Treat Biliary Cirrhosis Symptoms Phase 2
Completed NCT04629456 - Physical Therapy for Liver Cirrhosis N/A
Completed NCT03468699 - Autologous Bone Marrow Mononuclear Stem Cell for Children Suffering From Liver Cirrhosis Due to Biliary Atresia Phase 2
Completed NCT00006168 - Ursodiol-Methotrexate for Primary Biliary Cirrhosis Phase 3
Completed NCT00004784 - Phase III Randomized Study of Ursodiol With Vs Without Methotrexate for Primary Biliary Cirrhosis Phase 3
Completed NCT00570765 - Study of INT-747 as Monotherapy in Participants With Primary Biliary Cirrhosis (PBC) Phase 2
Recruiting NCT00160940 - Differential Gene Expression of Liver Tissue and Blood From Individuals With Chronic Viral Hepatitis N/A
Recruiting NCT03146910 - Swiss Primary Biliary Cholangitis Cohort Study
Terminated NCT03265249 - BRIDGE Device for Post-operative Pain Control N/A
Terminated NCT02308111 - Phase 4 Study of Obeticholic Acid Evaluating Clinical Outcomes in Patients With Primary Biliary Cholangitis Phase 4
Recruiting NCT02936596 - Remission Induction of Primary Biliary Cholangitis-autoimmune Hepatitis Overlap Syndrome N/A
Completed NCT00406237 - Pharmacokinetic Study Of Tigecycline In Adult Subjects With Primary Biliary Cirrhosis Phase 1
Completed NCT04047160 - Safety, Tolerability of OP-724 in Patients With Primary Biliary Cholangitis (Phase I) Phase 1
Recruiting NCT00145964 - Identification of the Genetic Variants Responsible for Primary Biliary Cirrhosis (PBC) N/A